Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Management of Hidradenitis Suppurativa: From Diagnosis to Treatment Options
Description
The presentation by Jenny Xiao from the University of Southern California focuses on the management of Hidradenitis Suppurativa (HS), emphasizing the importance of early diagnosis and appropriate treatment. She highlights the varying severity of HS, categorized into Hurley stages, and underscores the necessity for healthcare providers to build trust with patients, many of whom have seen multiple practitioners. The discussion includes the psychological comorbidities prevalent among HS patients, screening for depression, and the importance of a collaborative approach involving primary care providers. Treatment strategies for mild HS include lifestyle modifications, topical treatments, and systemic antibiotics, while moderate to severe cases may require biologics such as adalimumab and secukinumab. Diagnostic and therapeutic procedures, including incision and drainage, de-roofing, and laser therapy, are also presented as critical management components. Xiao recommends a multidisciplinary approach, incorporating mental health resources and community support to enhance patient care. She shares her clinical experiences and concludes with encouragement for ongoing research and collaboration in developing effective therapies.
View moreConclusions
- Early diagnosis and effective management of Hidradenitis Suppurativa (HS) can significantly mitigate disease progression and improve patient quality of life.
- Building rapport and trust with patients is essential to overcome prior negative healthcare experiences and enhance treatment adherence.
- Hidradenitis Suppurativa is associated with several comorbidities, including obesity, diabetes, and psychological disorders, which must be addressed in treatment plans.
- Lifestyle modifications such as smoking cessation and weight management are important components of HS management.
- Topical treatments like antiseptic washes and antibiotics should be considered for mild cases of HS, while systemic antibiotics and hormonal therapies are more appropriate for moderate to severe cases.
- Biologic therapies such as Adalimumab and Secukinumab are effective options for moderate to severe HS, with recent approvals expanding treatment options.
- Combination therapies, including the use of different types of biologics or adding adjunctive medications, can enhance treatment efficacy for difficult-to-treat patients.
- Procedural interventions like incision and drainage, de-roofing, and laser therapy play a crucial role in treating HS and providing symptomatic relief.
- Regular monitoring and adaptation of therapeutic strategies are necessary to achieve and maintain treatment response in HS patients.
- Patel et al. Curr Pain Headache Rep. 2017
- Garg et al. J Am Acad Dermatol. 2021
- Masson et al. JAAD Case Reports. 2023
- Alikhan et al. J Am Acad Dermatol. 2019
- Kimball et al. NEJM. 2016
- Casseres et al. J Am Acad Dermatol. 2020
- Marasca et al. JAAD Case Rep. 2019
- Kimball et al. Lancet. 2023
- Ghias et al. J Am Acad Dermatol. 2019; Oskardmay et al. J Am Acad Dermatol. 2019; Grant et al. J Am Acad Dermatol. 2010; Lesage et al. Eur J Dermatol. 2012; Paradela et al. J Dermatol Treat. 2012
- Blok et al. Br J Dermatol. 2016
- Romani et al. Dermatology. 2020; Jiang et al. Br J Dermatol. 2022
- Kozera et al. JAAD. 2022
- Maronese et al. Br J Dermatol. 2023
- Maronese et al. Expert Rev Clin Immunol. 2023
- Feagan et al. Lancet Gastroenterol Hepatol. 2023
- Bechara et al, JAMA Surgery 2021
- Dermatologic Therapy 2022